| The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. | |
| | |
MedLine Citation:
|
PMID: 17237285 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Poh1 deubiquitinase activity is required for proteolytic processing of polyubiquitinated substrates by the 26S proteasome, linking deubiquitination to complete substrate degradation. Poh1 RNA interference (RNAi) in HeLa cells resulted in a reduction in cell viability and an increase in polyubiquitinated protein levels, supporting the link between Poh1 and the ubiquitin proteasome pathway. To more specifically test for any requirement of the zinc metalloproteinase motif of Poh1 to support cell viability and proteasome function, we developed a RNAi complementation strategy. Effects on cell viability and proteasome activity were assessed in cells with RNAi of endogenous Poh1 and induced expression of wild-type Poh1 or a mutant form of Poh1, in which two conserved histidines of the proposed catalytic site were replaced with alanines. We show that an intact zinc metalloproteinase motif is essential for cell viability and 26S proteasome function. As a required enzymatic component of the proteasome, Poh1 is an intriguing therapeutic drug target for cancer. |
| | |
Authors:
|
Melissa Gallery; Jonathan L Blank; Yinghui Lin; Juan A Gutierrez; Jacqueline C Pulido; David Rappoli; Sunita Badola; Mark Rolfe; Kyle J Macbeth |
Related Documents
:
|
17082585 - E2-2 regulates the expansion of pro-b cells and follicular versus marginal zone decisions. 11809845 - Two splice variants of nopp140 in drosophila melanogaster. 22465675 - Sirna and pharmacological inhibition of endocytic pathways to characterize the differen... 8021595 - Human papillomavirus (hpv) type 18 e7 protein is a short-lived steroid-inducible phosph... 7528375 - Anti-human immunodeficiency virus type 1 activity of phosphorothioate analogs of oligod... 19508905 - Cell-matrix interactions and dynamic mechanical loading influence chondrocyte gene expr... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Molecular cancer therapeutics Volume: 6 ISSN: 1535-7163 ISO Abbreviation: Mol. Cancer Ther. Publication Date: 2007 Jan |
Date Detail:
|
Created Date: 2007-01-22 Completed Date: 2007-03-16 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101132535 Medline TA: Mol Cancer Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 262-8 Citation Subset: IM |
Affiliation:
|
Millennium Pharmaceuticals, Inc., 40 Landsdowne Street, Cambridge, MA 02139, USA. kyle.macbeth@mpi.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Amino Acid Motifs Cell Survival Hela Cells Humans Mutant Proteins / metabolism Proteasome Endopeptidase Complex / chemistry*, deficiency, metabolism* RNA Interference Trans-Activators / chemistry*, deficiency, metabolism* Ubiquitin / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Mutant Proteins; 0/PSMD14 protein, human; 0/Trans-Activators; 0/Ubiquitin; EC 3.4.25.1/Proteasome Endopeptidase Complex; EC 3.4.99.-/ATP dependent 26S protease |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT path...
Next Document: Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells.